Evidence map›Paper›PMID 31928222›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2020

Nanoformulated SOD1 ameliorates the combined NASH and alcohol-associated liver disease partly via regulating CYP2E1 expression in adipose tissue and liver.

Thiyagarajan Gopal, Narendra Kumar, Curtis Perriotte-Olson, Carol A Casey, Terrence M Donohue, Edward N Harris, Geoffrey Talmon, Alexander V Kabanov, Viswanathan Saraswathi

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Pathogenesis of Alcohol-Associated Liver Disease.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Thiyagarajan GopalDivision of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Narendra KumarDivision of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Curtis Perriotte-OlsonDivision of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Carol A CaseyDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Terrence M DonohueDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Edward N HarrisDepartment of Biochemistry, University of Nebraska Lincoln, Lincoln, Nebraska.
Geoffrey TalmonDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska.
Alexander V KabanovDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina.
Viswanathan SaraswathiDivision of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
University of Nebraska Medical Center · USVA Nebraska Western Iowa Health Care System · USUniversity of Nebraska–Lincoln · USUniversity of North Carolina at Chapel Hill · US

Funding

Altered Histidine Metabolism in Pancreatic Cancer: A Novel Metabolic Target to Enhance Gemcitabine EfficacyR21CA238953 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI RACHAGANI, SATYANARAYANA, VISWANATHAN, SARASWATHI · 2019 to 2020
$372k
The Role of TP-R on Adipose Tissue Browning: Therapeutic Implications in Alcoholic and Non-Alcoholic Fatty Liver DiseaseR21AA027367 · NIAAA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CASEY, CAROL A., VISWANATHAN, SARASWATHI · 2019 to 2020
$337k
The Effectiveness of NanoSOD in Ameliorating Ethanol-induced Liver Injury in ObesityR21AA025445 · NIAAA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI VISWANATHAN, SARASWATHI · 2017 to 2018
$331k
NCI NIH HHS R21 CA238953NIAAA NIH HHS R21 AA025445NIAAA NIH HHS R21 AA027367
6 · The paper itself

Abstract

Enhanced free fatty acid (FFA) flux from adipose tissue (AT) to liver plays an important role in the development of nonalcoholic steatohepatitis (NASH) and alcohol-associated liver disease (AALD). We determined the effectiveness of nanoformulated superoxide dismutase 1 (Nano) in attenuating liver injury in a mouse model exhibiting a combination of NASH and AALD. Male C57BL6/J mice were fed a chow diet (CD) or a high-fat diet (HF) for 10 wk followed by pair feeding of the Lieber-DeCarli control (control) or ethanol (ET) diet for 4 wk. Nano was administered once every other day for the last 2 wk of ET feeding. Mice were divided into

Indexed as

NanoparticlesAdiposityAnimalsCatalaseChemokine CCL2Cytochrome P-450 CYP2E1Disease Models, AnimalDrug CompoundingFatty Liver, AlcoholicGene Expression RegulationIntra-Abdominal FatLipolysisLiverMaleMice, Inbred C57BLNanomedicineCatalaseCcl2 protein, mouseChemokine CCL2Cytochrome P-450 CYP2E1Perilipin-1Plin1 protein, mouseSuperoxide Dismutase-1AALDcatalasecytochrome P450 2E1ethanolsuperoxide dismutase

Identifiers

PMID31928222
PMCPMC7099493
OpenAlexW2999854159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.